Blue Cross of Idaho Logo

Express Sign-on

Thank you for registering with Blue Cross of Idaho

If you are an Individual or Family Member under age 65, please register here.

If you are an Medicare or Medicare Supplement member, please register here.

New Options for Affordable Health Insurance

MP 2.01.87

Confocal Laser Endomicroscopy


Medical Policy     
Section
Medicine 
Original Policy Date
01/2013
Last Review Status/Date
Created with literature search/1:2013
Issue
1:2013
  Return to Medical Policy Index

Disclaimer

Our medical policies are designed for informational purposes only and are not an authorization, or an explanation of benefits, or a contract. Receipt of benefits is subject to satisfaction of all terms and conditions of the coverage. Medical technology is constantly changing, and we reserve the right to review and update our policies periodically.


Description

Confocal laser endomicroscopy (CLE), also known as confocal fluorescent endomicroscopy and optical endomicroscopy, allows in vivo microscopic imaging of cells during endoscopy. CLE is proposed for a variety of purposes, especially as a real-time alternative to histology during colonoscopy and for targeting areas to undergo biopsy in patients with inflammatory bowel disease and Barrett’s esophagus.

Confocal laser endomicroscopy (CLE), also known as confocal fluorescent endomicroscopy and optical endomicroscopy, allows in vivo microscopic imaging of the mucosal epithelium during endoscopy. According to the American Society for Gastrointestinal Endoscopy (ASGE), (1) with CLE, light from a low-power laser illuminates tissue and, subsequently, the same lens detects light reflected from the tissue through a pinhole. The term confocal refers to having both illumination and collection systems in the same focal plane. Light reflected and scattered at other geometric angles that is not reflected through the pinhole is excluded from detection which dramatically increases the special resolution of CLE images.

To date, 2 types of CLE systems have been cleared by the U.S. Food and Drug Administration (FDA). One is an endoscope-based system in which a confocal probe is incorporated onto the tip of a conventional endoscope. The other is a probe-based system; the probe is placed through the biopsy channel of a conventional endoscope. The depth of view is up to 250 um with the endoscopic system and about 120 um with the probe-based system. A limited area can be examined; no more than 700 um in the endoscopic-based system and less with the probe-based system. As pointed out in review articles, the limited viewing area emphasizes the need for careful conventional endoscopy to target the areas for evaluation. Both CLE systems are optimized using a contrast agent. The most widely used agent is intravenous fluorescein, which is FDA-approved for ophthalmologic imaging of blood vessels when used with a laser scanning ophthalmoscope.

Unlike techniques such as chromoendoscopy (see policy 2.01.84), which are primarily intended to improve the sensitivity of colonoscopy, CLE is unique in that it is designed to immediately characterize the cellular structure of lesions. CLE can thus potentially be used to make a diagnosis of polyp histology, particularly in association with screening or surveillance colonoscopy, which could allow for small hyperplastic lesions to be left in place rather than removed and sent for histological evaluation. This would reduce risks associated with biopsy and reduce the number of biopsies and histological evaluations. Another key potential application of CLE technology is targeting areas for biopsy in patients with Barrett’s esophagus undergoing surveillance endoscopy. This is an alternative to conducting random biopsies during surveillance and has the potential to reduce the number of biopsies and/or improve the detection of dysplasia. Other potential uses of CLE under investigation include better diagnosis and differentiation of conditions such as gastric metaplasia, lung cancer and bladder cancer.

As noted previously, limitations of CLE systems include a limited viewing area and depth of view. Another issue is standardization of systems for classifying lesions viewed with CLE devices. Although there is not currently an internationally accepted classification system for colorectal lesions, 2 systems have been developed that have been used in a number of studies conducted in different countries. These are the Mainz criteria for endoscopy-based CLE devices and the Miami classification system for probe-based CLE devices. (2) Lesion classification systems are less developed for non-gastrointestinal lesions viewed by CLE devices e.g., those in the lung or bladder. Another potential issue is the learning curve for obtaining high-quality images and classifying lesions. Several recent studies, however, have found that the ability to acquire high-quality images and interpret them accurately can be learned relatively quickly; these studies were limited to colorectal applications of CLE. (3, 4)

Regulatory Status

Two confocal laser endomicroscopy devices have been cleared for marketing by the FDA. These include:

Cellvizio (Mauna Kea Technologies; Paris, France): This is a confocal microscopy with a fiber optic probe (i.e., a probe-based CLE system). The device consists of a laser scanning unit, proprietary software, a flat-panel display and miniaturized fiber optic probes. The F-600 system, cleared by the FDA in 2006, can be used with any standard endoscope with a working channel of at least 2.8 mm. According to FDA documents, the device is intended for confocal laser imaging of the internal microstructure of tissues in the anatomical tract (gastrointestinal or respiratory) that are accessed by an endoscope.

Confocal Video Colonoscope (Pentax Medical Company: Montvale, NJ): This is an endoscopy-based CLE system. The EC-3S7OCILK system, cleared by the FDA in 2004, is used with a Pentax Video Processor and with a Pentax Confocal Laser System. According to FDA materials, the intended use of the device is to provide optical and microscopic visualization of and therapeutic access to the lower gastrointestinal tract.


Policy

Use of confocal laser endomicroscopy is considered investigational.


Policy Guidelines

Beginning in 2013, there are specific CPT codes for the use of this technology:

43206 Esophagoscopy, rigid or flexible; with optical endomicroscopy

43252 Upper gastrointestinal endoscopy including esophagus, stomach, and either the duodenum and/or jejunum as appropriate; with optical endomicroscopy.

The interpretation and report of optical endomicroscopic image(s) would be reported with the following code:

88375: Optical endomicroscopic image(s), interpretation and report, real-time or referred, each endoscopic session.

Code 88375 cannot be reported in conjunction codes 43206 and 43252.


Benefit Application

BlueCard/National Account Issues

State or federal mandates (e.g., FEP) may dictate that all U.S. Food and Drug Administration (FDA)-approved devices, drugs, or biologics may not be considered investigational, and thus these devices may be assessed only on the basis of their medical necessity.


Rationale

Literature Review

This policy was created in with a search of the MEDLINE database through November 2012.

Following is a summary of the key literature.

Colorectal lesions

What is the accuracy of confocal laser endomicroscopy (CLE) compared to biopsy with histology for analysis of colorectal lesions?

The ideal study to answer this question would include an unselected clinical population presenting for screening colonoscopy, use biopsy and histology as the reference standard, include blinded analysis of CLE findings and use an accepted standardized method of CLE analysis.

Individuals at increased risk of colorectal cancer

In 2012, a systematic review and meta-analysis of studies evaluating the efficacy of CLE for discriminating colorectal neoplasms from non-neoplasms was accepted for publication. (5) The review, by Su and colleagues, included studies that used histological biopsy as the reference standard and in which the pathologist and endoscopist were blinded to each other’s findings. Included studies also used a standardized CLE classification system. Patient populations in included studies were individuals at increased risk of colorectal cancer due to personal or family history, patients with previously identified polyps, and/or patients with inflammatory bowel disease (IBD). Two reviewers independently assessed the quality of individual studies using the modified quality assessment of diagnostic accuracy studies (QUADAS) tool, and studies considered to be at high-risk of bias were excluded from further consideration.

A total of 15 studies with 719 adult patients were found to be eligible for the systematic review. All were single-center trials and 2 were available only as abstracts. In all the studies, suspicious lesions were first identified by conventional white-light endoscopy with or without chromoendoscopy and then further examined by CLE. A pooled analysis of the 15 studies found an overall sensitivity of CLE of 94% (95% confidence interval [CI]: 0.88 to 0.97) and specificity of 95% (95% CI: 0.89 to 0.97), compared to histology.

Six of the studies included patients at increased risk of colorectal cancer (CRC) who were undergoing surveillance endoscopy, 5 studies included patients with colorectal polyps and 4 studies included patients with IBD. In a pre-defined subgroup analysis by indication for screening, the pooled sensitivity and specificity for surveillance studies was 94% (95% CI: 90 to 97%) and 98% (95% CI: 97 to 99%) respectively. For patients presenting with colorectal polyps, the pooled sensitivity of CLE was 91% (95% CI:: 87 to 94%) and specificity was 85% (95% CI: 78 to 90%). For patients with IBD, the pooled sensitivity was 83% (95% CI: 70 to 92%) and specificity was 90% (95% CI: 87 to 93%). In other pre-defined subgroup analyses, the summary sensitivity and specificity was significantly higher (p<0.001) in studies of endoscopy-based CLE (97% and 99%, respectively) than studies of probe-based CLE (87% and 82%, respectively). In addition, the summary sensitivity and specificity was significantly higher (p<0.01) with real-time CLE in which the macroscopic endoscopy findings were known (96% and 97%, respectively) than with blinded CLE in which recorded confocal images were subsequently analyzed without knowledge of macroscopic endoscopy findings (85% and 82%, respectively).

Representative studies are described below:

A 2011 study by Xie and colleagues in China included 116 consecutive patients who had polyps found during CLE; 1 patient was excluded from the analysis. All patients had an indication for colonoscopy (19 were undergoing surveillance post-polypectomy, 2 had a family history of colorectal cancer, 3 had IBD and 91 were seeking a diagnosis). All patients first underwent white-light colonoscopy. Endoscopy-based CLE was used on the first polyp identified during withdrawal of the endoscope (i.e., one polyp per patient was analyzed). Intravenous fluorescein sodium was used. Real-time diagnosis of the polyp was performed based on criteria used at the study center (which is adapted from the Mainz classification system). The polyps were then underwent biopsy or were removed and histopathological diagnosis was determined. Real-time CLE diagnosis correctly identified 109 of 115 (95%) adenomas or hyperplastic polyps. Four adenomas were misdiagnosed by CLE as hyperplastic polyps (2 were tubulous adenomas and 2 were tubulovillous adenomas) and 2 hyperplastic polyps were misdiagnosed as adenomas. The overall sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of CLE diagnosis was 93.9% (95% CI: 85.4 to 97.6%), 95.9% (95% CI: 86.2 to 98.9%), 96.9% (95% CI: 89 to 99%), and 94.8% (95% CI: 89.1 to 97.6%), respectively. For polyps less than 10 mm, the CLE diagnosis had a sensitivity of 90.3% and specificity of 95.7% and for polyps 10 mm and larger, sensitivity was 97.1% and specificity was 100%. (6)

In 2010, Buchner and colleagues at Mayo Clinic published findings on 75 patients who had a total of 119 polyps. (7) Patients were eligible for study participation if they were undergoing surveillance or screening colonoscopy or undergoing evaluation of known or suspected polyps identified by other imaging modalities or endoscopic resection of larger flat colorectal neoplasia. White-light colonoscopy was used as the primary screening method. When a suspicious lesion was identified, it was evaluated by virtual chromoendoscopy system and a probe-based CLE system. Intravenous fluorescein sodium was administered after the first polyp was identified. Following the imaging techniques, the appropriate intervention, i.e., polypectomy, biopsy, or endoscopic mucosal resection, of lesions were performed and all resected specimens underwent histopathological analysis by a pathologist blinded to CLE information. Confocal images of the 119 polyps were evaluated after all procedures were completed; the evaluator was blinded to histology diagnosis and endoscopic appearance of the lesion. Diagnosis of confocal images used modified Mainz criteria; polyps were classified as benign or neoplastic. According to histopathological analysis, there were 38 hyperplastic polyps and 81 neoplastic lesions (58 tubular adenomas, 15 tubulovillous adenomas and 4 adenocarcinomas). CLE correctly identified 74 of 81 neoplastic polyps (sensitivity: 91%, 95% CI: 83 to 96%). In addition, CLE correctly identified 29 of 38 hyperplastic polyps (specificity: 76%, 95% CI: 60 to 89%). In contrast, virtual chromoendoscopy correctly identified 62 neoplastic polyps (sensitivity: 77%, 95% CI: 66 to 85%) and 27 hyperplastic polyps (specificity: 71%, 95% CI: 54 to 85% ).

Another Mayo Clinic study was published in 2012 by Shadid and colleagues. (8) The focus of the study was to compare 2 methods of analyzing CLE images: real-time diagnosis and blinded review of video images after endoscopy (known as “offline” diagnosis).The study included 74 patients with a total of 154 colorectal lesions. Eligibility criteria were similar to the Buchner et al. study (see above); the included patients undergoing surveillance or screening colonoscopy for evaluation of known or suspected polyps.

Patients underwent white-light colonoscopy and identified polyps were also evaluated with virtual chromoendoscopy and probe-based CLE. Intravenous fluorescein sodium was administered after the first polyp was identified. At the time of examination, an endoscopist made a real-time diagnosis based on CLE images. Based on that diagnosis, the patient underwent polypectomy, biopsy or endoscopic mucosal resection, and histopathological analysis was done on the specimens. The CLE images were then de-identified and then reviewed off-line by the same endoscopist at least one month later. At the second review, the endoscopist was blinded to the endoscopic and histopathological diagnosis. Of the 154 polyps, 74 were found by histopathological analysis to be non-neoplastic and 80 were neoplastic (63 tubular adenomas, 12 tubulovillous adenomas, 3 mixed hyperplastic-adenoma polyps and 2 adenocarcinomas). Overall, there was not a statistically significant difference in the diagnostic accuracy of real-time CLE diagnosis and blinded offline CLE diagnosis (i.e., confidence intervals overlapped). The sensitivity, specificity, PPV and NPV for real-time CLE diagnosis was 81%, 76%, 87% and 79%, respectively. For offline diagnosis, these numbers were 88%, 77%, 81% and 85%, respectively. However, in the subgroup of 107 smaller polyps less than 10 mm in size, the accuracy of real-time CLE was significantly lower than offline CLE. For the smaller polyps, sensitivity, specificity, PPV and NPV of real-time CLE was 71%, 83%, 78% and 78% and for offline CLE was 86%, 78%, 76% and 87%, all respectively. For larger polyps, in contrast, there was a non-significant trend in favor of better diagnostic accuracy with real-time compared to offline CLE.

A 2011 study by Hlavaty and colleagues in Slovakia included patients with ulcerative colitis or Crohn’s disease. (9) Thirty patients were examined with standard white-light colonoscopy, chromoendoscopy and an endoscopy-based CLE system. An additional 15 patients were examined only with standard colonoscopy. All lesions identified by white-light colonoscopy or chromoendoscopy were examined using CLE to identify neoplasia using the Mainz classification system. Suspicious lesions underwent biopsy and, additionally, random biopsies were taken from 4 quadrants every 10 cm per the standard surveillance colonoscopy protocol. All specimens underwent histological analysis by a gastrointestinal pathologist who was blinded to the CLE diagnosis. Diagnostic accuracy of CLE was calculated for examinable lesions only. Compared to histological diagnosis, the sensitivity of CLE for diagnosing low-grade and high-grade intraepithelial neoplasia was 100%, the specificity was 98.4%, the PPV was 66.7%, and the NPV was 100%. However, whereas CLE was able to examine 28 of 30 (93%) flat lesions, it could examine only 40 of 70 (57%) protruding polyps. Moreover, 6 of 10 (60%) dysplastic lesions, including 3 of 5 low-grade and high-grade intraepithelial neoplasms were not evaluable by CLE. It is also worth noting that the diagnostic accuracy of chromoendoscopy (considered investigational, see in policy 2.01.84) was similar to that of CLE. The sensitivity, specificity, PPV and NPV of chromoendoscopy was 100%, 97.9%, 75% and 100%, respectively.

Conclusions: Multiple studies have evaluated the diagnostic accuracy of confocal laser endoscopy compared to histopathology for patients at increased risk of colorectal cancer. A meta-analysis of diagnostic accuracy studies found a pooled sensitivity of 94% (95% CI: 0.88 to 0.97) and a pooled specificity of 95% (95% CI: 0.89 to 0.97). Although the reported diagnostic accuracy is high, it is not clear whether the accuracy is high enough to replace biopsy/polypectomy and histological analysis.

Barrett’s esophagus (BE)

What is the evidence that CLE with targeted biopsy can:

  • distinguish BE without dysplasia from BE with low- and high-grade dysplasia,
  • lead to fewer biopsies of benign tissue compared to surveillance with random biopsies?

The American Gastroenterological Association (AGA) recommends that patients with Barrett’s esophagus who do not have dysplasia undergo endoscopic surveillance every 3 to 5 years. (10) They further recommend that random 4-quadrant biopsies every 2 cm be taken with white-light endoscopy in patients without known dysplasia.

The ideal study to answer the above question would include an unselected clinical population of patients with Barrett’s esophagus presenting for surveillance and would randomly assign patients to CLE with targeted biopsy or a standard biopsy protocol without CLE. Relevant outcomes include diagnostic accuracy for detecting dysplasia, the detection rate for dysplasia, and the number of biopsies. Several studies with most or all of these elements of study design were identified, including randomized controlled trials. A description of representative randomized studies is included below.

In 2011, Sharma and colleagues published an international, multicenter RCT with sites in several European countries and the United States. (11) The study included 122 consecutive patients presenting for surveillance of Barrett’s esophagus or endoscopic treatment of high-grade dysplasia or early carcinoma. Patients were randomly assigned to receive, in random order, both standard white-light endoscopy and narrow-band imaging. Following these 2 examinations which were done in a blinded fashion, the location of lesions was unblinded and, subsequently, all patients underwent probe-based CLE. All examinations involved presumptive diagnosis of suspicious lesions. Also, in both groups, after all evaluations were performed, there were biopsies of all suspicious lesions, as well as biopsies of random locations (4 quadrants every 2 cm). The authors did not mention the criteria that were used to diagnose a lesion as dysplastic or non-dysplastic. Histopathological analysis was the reference standard. Twenty-one patients were excluded from the analysis. Of the remaining 101 patients, 66 (65%) were found on histopathological analysis to have no dysplasia, 4 (4%) had low-grade dysplasia, 6 (6%) had high-grade dysplasia and 25 (25%) had early carcinoma. The sensitivity of CLE with white-light endoscopy for detecting high-grade dysplasia or early carcinoma was 68.3% (95% CI: 60.0 to 76.7%), which was significantly higher than white-light endoscopy alone; 34.2% (95% CI: 25.7 to 42.7%, p=0.002). However, the specificity of CLE and white-light endoscopy was significantly lower than white-light endoscopy alone : 92.7% (95% CI: 90.8 to 94.6%) versus 87.8% (95% CI: 85.5 to 90.1%, p<0.001). For white-light endoscopy alone, the PPV was 42.7% (32.8 to 52.6%) and the NPV was 89.8% (95% CI: 87.7 to 92.0%). For white-light endoscopy with probe-based CLE, the PPV was 47.1% (95% CI: 39.7 to 54.5%) and the NPV was 94.6% (95% CI: 92.9 to 96.2%). White-light endoscopy alone missed 79 of 120 (66%) areas with high-grade dysplasia or early carcinoma and white-light endoscopy with CLE missed 38 (32%) areas. On a per patient basis, 31 patients were diagnosed with high-grade dysplasia or early carcinoma. White-light endoscopy alone failed to identify 4 of these patients (sensitivity: 87%) whereas white-light endoscopy and CLE failed to identify 2 patients (sensitivity: 93.5%).

Another RCT was published in 2012 by Bertani and colleagues in Italy; this was a single-center study. (12) The study compared the dysplasia detection rate of biopsies obtained by standard white-light endoscopy only to the detection rate with standard endoscopy followed by probe-based CLE in patients with Barrett’s esophagus who were enrolled in a surveillance program. One hundred consecutive patients were included and 50 were randomly assigned to each group. In both groups, targeted biopsies of suspicious lesions and random 4-quadrant biopsies (1 biopsy every 1 cm) were taken. The authors described the criteria they used for classifying CLE images as dysplastic or neoplastic. According to histopathological analysis, the reference standard, high-grade dysplasia was diagnosed in 3 patients and low-grade dysplasia was diagnosed in 16 patients, for an overall detection rate of 19 in 100 (19%) cases. Five cases were in the standard endoscopy group (1 case of high-grade dysplasia and 4 cases of low-grade dysplasia) and 14 were in the CLE group (2 cases of high-grade dysplasia and 12 cases of low-grade dysplasia). No suspicious lesions were identified in the standard endoscopy group and thus only random biopsies were performed. In the CLE group, no suspicious lesions were identified when patients were initially evaluated with standard endoscopy but CLE detected areas suspicious for neoplasia in 21 of 50 (42%) of patients. All the cases of dysplasia were in patients with areas suspicious for neoplasia at CLE but not standard endoscopy. The sensitivity, specificity, PPV and NPV of probe-based CLE for detecting dysplasia were 100%, 83%, 67% and 100%, respectively. Overall, the mean number of biopsies did not differ between groups (mean of 6.6 per patient in the standard endoscopy group and 6.1 in the CLE group, p=0.77) so the increased detection rate in the CLE group cannot be explained by a larger number of biopsies.

A single-center cross-over randomized controlled trial (RCT) was published in 2009 by Dunbar and colleagues. (13) This study was able to evaluate whether CLE can reduce the biopsy rate. Forty-six patients with Barrett’s esophagus (BE) were enrolled and 39 (95%) completed the study protocol. Of these, 23 were undergoing BE surveillance and 16 had BE with suspected neoplasia. All patients received endoscopy-based CLE and standard endoscopy, in random order. One endoscopist performed all CLE procedures and another endoscopist performed all standard endoscopy procedures; endoscopists were blinded to the finding of the other procedure. During the standard endoscopy procedure, biopsies were taken of any discrete lesions followed by 4-quadrant random biopsy (every 1 cm for suspected neoplasia and every 2 cm for BE surveillance). During the CLE procedure, only lesions suspicious of neoplasia were biopsied. Endoscopists interpreted CLE images using the “Confocal Barrett’s Classification” system, developed in a previous research study. Histopathological analysis was the reference standard. Among the 16 study completers with suspected high-risk dysplasia, there were significantly fewer biopsies per patient with CLE compared to standard endoscopy (mean of 9.8 biopsies versus 23.9 biopsies per patient, p=0.002). Although there were fewer biopsies, the mean number of biopsy specimens showing high-grade dysplasia or cancer was similar in the 2 groups: 3.1 during CLE and 3.7 during standard endoscopy, respectively. The diagnostic yield for neoplasia was 33.7% with CLE and 17.2% with standard endoscopy. None of the 23 patients undergoing BE for surveillance were found to have high-grade dysplasia or cancer. The mean number of mucosal specimens obtained for patients in this group was 12.6 with white-light endoscopy and 1.7 with CLE (p<0.001).

Conclusions: Several RCTs suggest that CLE has high accuracy for identifying dysplasia in patients with BE. The sensitivity of CLE in these studies was higher than for white-light endoscopy alone, but the specificity was not consistently higher. There are limited data comparing standard protocols using random biopsies to protocols using CLE and targeted biopsies, so data are inconclusive regarding the potential for CLE to reduce the number of biopsies in patients with BE undergoing surveillance without compromising diagnostic accuracy. Moreover, studies do not appear to use a consistent approach to classifying lesions viewed using CLE as dysplastic.

Other potential applications of CLE

Preliminary studies have been published evaluating CLE for diagnosing a variety of conditions including lung cancer, (14) bladder cancer, (15, 16) gastric cancer (17, 18) and bile duct malignancies. (19) There are insufficient studies to determine the accuracy of CLE for these applications and their potential role in clinical care in the United States.

Ongoing Clinical Trials

Confocal Laser Endomicroscopy for the Diagnosis of Gastric Intestinal Metaplasia, Intraepithelial Neoplasia, and Carcinoma (NCT01642797) (20): This double-blind randomized trial will include approximately 242 patients with Helicobacter pylori infection, gastric intestinal metaplasia, low-grade intraepithelial neoplasia or atrophic gastritis. Patients will receive either confocal laser endomicroscopy with targeted biopsy or standard white-light endoscopy with standard biopsy. The primary outcome measure is the diagnostic yield for identifying gastric intestinal metaplasia, intraepithelial neoplasia and carcinoma.

Comparison Between Probe-based Confocal Laser Endomicroscopy, White-light Endoscopy and Virtual Chromoendoscopy (pCLE-GCEP) (NCT01398579) (21): This is a single-blind randomized trial including an estimated 20 patients at increased risk of gastric cancer. All patients will be examined using 4 different endoscopy methods (CLE, white-light endoscopy, magnifying narrow-band imaging and autofluorescence imaging. Randomization will determine the order of the tests. The primary outcome is accuracy for diagnosing gastric pre-neoplastic and neoplastic lesions, using histopathology as the reference standard.

Summary

Confocal laser endomicroscopy (CLE) is a device that allows in vivo microscopic imaging of cells during endoscopy. For patients undergoing screening or surveillance colonoscopy, multiple studies have evaluated the diagnostic accuracy of CLE. While the reported sensitivity and specificity in these studies is high, it may not be sufficiently high to replace biopsy/polypectomy and histolopathologic analysis. Therefore, this evidence is not sufficient to conclude that CLE improves outcomes when used as an adjunct to colonoscopy.

Several studies have evaluated CLE for identifying areas of dysplasia and targeting biopsies in patients undergoing surveillance for Barrett’s esophagus. Evidence from RCTs supports that CLE is more sensitive than white-light endoscopy for identifying areas of dysplasia. However, this evidence is insufficient to determine the impact of this technology on health outcomes in this population, particularly outside of the research setting. National guidelines continue to recommend 4-quadrant random biopsies for patients with Barrett’s esophagus undergoing surveillance. There are less data on the use of CLE in non-gastrointestinal conditions such as lung or bladder cancer. Thus, use of CLE with endoscopy is considered investigational for all indications.

Practice Guidelines and Position Statements

In 2009, the American Society for Gastrointestinal Endoscopy (ASGE) Technology Committee published a report on confocal laser endomicroscopy. (1) The document concluded, “In recent years, confocal laser endomicroscopy rapidly moved from the bench to the bedside. It is being analyzed as a potentially valuable addition to conventional endoscopy as a means of in vivo optical biopsy enabling real-time histological examination of the superficial layer of the GI tract. How this will affect the practice of screening, surveillance, and early diagnosis of benign, premalignant, and malignant lesions of the GI tract requires further study.”

In 2006 (reaffirmed as current in 2011), ASGE published a guideline on the role of endoscopy in the surveillance of premalignant conditions of the upper gastrointestinal (GI) tract. (22) The guideline included the following statements on surveillance of patients with Barrett’s esophagus:

- “The cost effectiveness of surveillance in patients without dysplasia is controversial. Surveillance endoscopy is appropriate for patients fit to undergo therapy, should endoscopic/histologic findings dictate. For patients with established Barrett's esophagus of any length and with no dysplasia, after 2 consecutive examinations within 1 year, an acceptable interval for additional surveillance is every 3 years.”

- “Patients with high-grade dysplasia are at significant risk for prevalent or incident cancer. Patients who are surgical candidates may elect to have definitive therapy. Patients who elect surveillance endoscopy should undergo follow-up every 3 months for at least 1 year, with multiple large capacity biopsy specimens obtained at 1 cm intervals. After 1 year of no cancer detection, the interval of surveillance may be lengthened if there are no dysplastic changes on 2 subsequent endoscopies performed at 3-month intervals. High-grade dysplasia should be confirmed by an expert GI pathologist.”

- “Surveillance in patients with low-grade dysplasia is recommended. The significance of low-grade dysplasia as a risk factor for cancer remains poorly defined; therefore, the optimal interval and biopsy protocol has not been established. A follow-up EGD (screening esophagogastroduodenoscopy) (i.e., at 6 months) should be performed with concentrated biopsies in the area of dysplasia. If low-grade dysplasia is confirmed, then one possible management scheme would be surveillance at 12 months and yearly thereafter as long as dysplasia persists.”

In 2011, the American Gastroenterological Association (AGA) published a position statement on the management of Barrett's esophagus. (10) The statement included the following recommendations regarding endoscopic surveillance of Barrett's esophagus:

The guideline developers suggest that endoscopic surveillance be performed in patients with Barrett's esophagus (weak recommendation, moderate-quality evidence).

The guideline developers suggest the following surveillance intervals (weak recommendation, low-quality evidence):

  • No dysplasia: 3–5 years
  • Low-grade dysplasia: 6–12 months
  • High-grade dysplasia in the absence of eradication therapy: 3 months

For patients with Barrett's esophagus who are undergoing surveillance, the guideline developers recommend:

  • Endoscopic evaluation be performed using white light endoscopy (strong recommendation, moderate-quality evidence).
  • 4-quadrant biopsy specimens be taken every 2 cm (strong recommendation, moderate-quality evidence).
  • Specific biopsy specimens of any mucosal irregularities be submitted separately to the pathologist (strong recommendation, moderate-quality evidence).
  • 4-quadrant biopsy specimens be obtained every 1 cm in patients with known or suspected dysplasia (strong recommendation, moderate-quality evidence).

The guideline developers suggest against requiring chromoendoscopy or advanced imaging techniques for the routine surveillance of patients with Barrett's esophagus at this time (weak recommendation, low-quality evidence).

Medicare National Coverage

No national coverage determination.

 References:

  1. American Society for Gastrointestinal Endoscopy Technology Committee. Confocal laser endomicroscopy. Available online at: http://www.asge.org/uploadedFiles/Publications_and_Products/Practice_Guidelines/confocal.pdf. Last accessed December, 2012.
  2. Salvatori F, Siciliano S, Maione F et al. Confocal Laser Endomicroscopy in the Study of Colonic Mucosa in IBD Patients: A Review. Gastroenterol Res Pract 2012; 2012:525098.
  3. Neumann H, Vieth M, Atreya R et al. Prospective evaluation of the learning curve of confocal laser endomicroscopy in patients with IBD. Histol Histopathol 2011; 26(7):867-72.
  4. Buchner AM, Gomez V, Heckman MG et al. The learning curve of in vivo probe-based confocal laser endomicroscopy for prediction of colorectal neoplasia. Gastrointest Endosc 2011; 73(3):556-60.
  5. Su P, Liu Y, Lin S et al. Efficacy of confocal laser endomicroscopy for discriminating colorectal neoplasms from non-neoplasms: a systematic review and meta-analysis. Colorectal Dis 2012 [Epub ahead of print].
  6. Xie XJ, Li CQ, Zuo XL et al. Differentiation of colonic polyps by confocal laser endomicroscopy. Endoscopy 2011; 43(2):87-93.
  7. Buchner AM, Shahid MW, Heckman MG et al. Comparison of probe-based confocal laser endomicroscopy with virtual chromoendoscopy for classification of colon polyps. Gastroenterology 2010; 138(3):834-42.
  8. Shahid MW, Buchner AM, Raimondo M et al. Accuracy of real-time vs. blinded offline diagnosis of neoplastic colorectal polyps using probe-based confocal laser endomicroscopy: a pilot study. Endoscopy 2012; 44(4):343-8.
  9. Hlavaty T, Huorka M, Koller T et al. Colorectal cancer screening in patients with ulcerative and Crohn's colitis with use of colonoscopy, chromoendoscopy and confocal endomicroscopy. Eur J Gastroenterol Hepatol 2011; 23(8):680-9.
  10. Spechler SJ, Sharma P, Souza RF et al. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. 2011. Available online at: www.guideline.gov. Last accessed December, 2012.
  11. Sharma P, Meining AR, Coron E et al. Real-time increased detection of neoplastic tissue in Barrett's esophagus with probe-based confocal laser endomicroscopy: final results of an international multicenter, prospective, randomized, controlled trial. Gastrointest Endosc 2011; 74(3):465-72.
  12. Bertani H, Frazzoni M, Dabizzi E et al. Improved detection of incident dysplasia by probe-based confocal laser endomicroscopy in a Barrett's esophagus surveillance program. Dig Dis Sci 2012 [Epub ahead of print].
  13. Dunbar KB, Okolo P, 3rd, Montgomery E et al. Confocal laser endomicroscopy in Barrett's esophagus and endoscopically inapparent Barrett's neoplasia: a prospective, randomized, double-blind, controlled, crossover trial. Gastrointest Endosc 2009; 70(4):645-54.
  14. Fuchs FS, Zirlik S, Hildner K et al. Confocal laser endomicroscopy for diagnosing lung cancer in vivo. Eur Resp J 2012 [Epub ahead of print].
  15. Sonn GA, Jones SN, Tarin TV et al. Optical biopsy of human bladder neoplasia with in vivo confocal laser endomicroscopy. J Urol 2009; 182(4):1299-305.
  16. Liu JJ, Droller MJ, Liao JC. New optical imaging technologies for bladder cancer: considerations and perspectives. J Urol 2012; 188(2):361-8.
  17. Wang SF, Yang YS, Wei LX et al. Diagnosis of gastric intraepithelial neoplasia by narrow-band imaging and confocal laser endomicroscopy. World J Gastroenterol 2012; 18(34):4771-80.
  18. Li WB, Zuo XL, Li CQ et al. Diagnostic value of confocal laser endomicroscopy for gastric superficial cancerous lesions. Gut 2011; 60(3):299-306.
  19. Smith I, Kline PE, Gaidhane M et al. A review on the use of confocal laser endomicroscopy in the bile duct. Gastroenterol Res Pract 2012; 2012:454717.
  20. Sponsored by Shandong University. Confocal Laser Endomicroscopy for the Diagnosis of Gastric Intestinal Metaplasia, Intraepithelial Neoplasia, and Carcinoma (NCT01642797). Available online at: www.clinicaltrials.gov. Last accessed December, 2012.
  21. Sponsored by National University Hospital (Singapore). Comparison Between Probe-based Confocal Laser Endomicroscopy, White-light Endoscopy and Virtual Chromoendoscopy (pCLE-GCEP) (NCT01398579). Available online at: www.clinicaltrials.gov. Last accessed December, 2012.
  22. Hirota WK, Zuckerman MJ, Adler DG et al. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. 2006. Available online at: www.guideline.gov. Last accessed December, 2012.

 

Codes

Number

Description

CPT

43206

Esophagoscopy, rigid or flexible; with optical endomicroscopy

  43252 Upper gastrointestinal endoscopy including esophagus, stomach, and either the duodenum and/or jejunum as appropriate; with optical endomicroscopy
  88375 Optical endomicroscopic image(s), interpretation and report, real-time or referred, each endoscopic session.

ICD-9-CM Diagnosis

 

Investigational for all relevant diagnoses

ICD-10-CM (effective 10/1/14)   Investigational for all relevant diagnoses
  K22.70-K22.719

Barrett's esophagus code range

  Z13.810 Encounter for screening for upper gastrointestinal disorder
  Z13.811 Encounter for screening for lower gastrointestinal disorder
  Z13.83 Encounter for screening for respiratory disorder NEC 
ICD-10-PCS (effective 10/1/14)    ICD-10-PCS codes are only used for inpatient services. There is no specific ICD-10-PCS code for the use of this technology.


Index
Confocal fluorescent endomicroscopy
Optical endomicroscopy
Pentax Confocal Laser System
Cellvizio

Policy History

Date Action Reason
01/10/13 Add to Medicine section Policy created with literature search through November 2012; considered investigational.
3/14/13 Replace policy-correction only Correction of typographical error in the Rationale discussion of Buchner 201 (reference 7)